GoodRx Holdings, Inc. Class A Common Stock (GDRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XFRA 
Unveiling GoodRx (GDRX) Q2 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for GoodRx (GDRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
GoodRx Q2 Earnings Preview
GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance doesn't support current price point. Upside potential if GoodRx doubles market growth, but industry headwinds and growth struggles pose challenges.
3 Lawsuit-Laden Stocks to Dump Before Problems Multiply
A pending or ongoing lawsuit isn't always a reliable indicator of stocks to sell, but, in many cases, investors should take litigation as a sign to dig beneath the surface. I'd first caution retail investors not to take pending litigation as a sure sign of failure or risk; tons of legal firms push frivolous lawsuits in a bid to maximize their own income.
Drug prices have risen almost 40% over the last decade, according to a new tracker
The cost of prescription medications in the U.S. has increased by 37% since 2014, far surpassing the rate of inflation, according to data from drug savings company GoodRx. Though the price increases have slowed this year in comparison with the past decade, the average American spends $16.26 out of pocket per prescription, according to the data.
GoodRx Debuts Tracker to Monitor Out-of-Pocket Prescription Costs
GoodRx aims to give consumers a better handle on prescription affordability. The prescription savings platform introduced its Prescription Cost Tracker to monitor out-of-pocket prescription spending trends in the United States, according to a Wednesday (June 26) press release.
June 21, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against GDRX
NEW YORK, NY / ACCESSWIRE / June 21, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors With Losses In GoodRx Holdings Inc Are Encouraged By The Schall Law Firm To Make Contact Before The Deadline
LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.
Shareholders that lost money on GoodRx Holdings, Inc.(GDRX) should contact Levi & Korsinsky about pending Class Action - GDRX
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Shareholders of GoodRx Holdings, Inc.(GDRX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Encourages Investors Who Have Suffered Losses With GoodRx Holdings Inc To Make Contact Before The Deadline
LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.
Shareholders that lost money on GoodRx Holdings, Inc.(GDRX) should contact Levi & Korsinsky about pending Class Action - GDRX
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)
RADNOR, PA / ACCESSWIRE / June 20, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company") on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period"). This action, captioned Barsuli v.
